Safety and Efficacy of Nemolizumab in PN

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

September 26, 2018

Study Completion Date

September 26, 2018

Conditions
Prurigo Nodularis
Interventions
DRUG

CD14152 Dose A

3 subcutaneous injections (every 4 weeks during the 12-week treatment period)

DRUG

CD14152 placebo

3 subcutaneous injections (every 4 weeks during the 12-week treatment period)

Trial Locations (16)

Unknown

LKH-Univ. Klinikum Graz, Graz

Centre-Hospitalier Universitaire (CHU) - Hopital Morvan - Br, Brest

CHU de Nice - Hôpital Archet 2, Nice

Hopital Saint-Louis - Dermatology, Paris

Centre Hospitalier Universitaire De Toulouse, Toulouse

Charite - Campus Charite Mitte (CCM) - Dermatologie & Allergologie - Dermatologie & Allergologie, Berlin

Universitätsklinikum Bonn AöR, Bonn

Klinikum der Johann-Wolfgang Goethe-Universität, Frankfurt

Unikl. Schleswig-Holstein - Lübeck, Lübeck

Universitätsmedizin Mainz, Mainz

Klinikum Der Universität München - Campus Innenstadt - Dermatologie und Allergologie, München

Universitätsklinikum Münster, Münster

Eberhard-Karls Universitaet Tuebingen - Universitaets Hautkl, Tübingen

Centrum Medyczne DERMED, Lodz

Dermoklinika Centrum Medyczne s.c. M.Kierstan, J.Narbutt, A.Lesiak, Lodz

Kliniczny Szpital Wojew. nr 1 im. F.Chopina w Rzeszowie, Rzeszów

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY